Prerna Mewawalla, Myeloma and Transplant Physician, Associate Professor at Drexel University College of Medicine, shared a post on LinkedIn:
“It was a privilege to present on Advances in CAR-T Therapies for Multiple Myeloma at the ICE-T Congress University of Kansas Medical Center and to join expert panels on CAR-T and bispecific antibodies.
CAR-T has already transformed outcomes in relapsed/refractory myeloma, and the field is moving quickly toward earlier integration, stronger durability, and broader access.
Equally exciting is what lies ahead:
- Anito-cel and Arlo-cel
- NK-based CAR-T therapies
- Dual-targeted constructs
These next-generation strategies will further expand the boundaries of cellular therapy and redefine what’s possible for patients.
Grateful for the engaging discussions and collaboration with colleagues from across the country.”
More posts featuring Prerna Mewawalla.
